{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:05:11Z","timestamp":1746338711115},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1097\/md.0000000000008470","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T22:01:19Z","timestamp":1509573679000},"page":"e8470","source":"Crossref","is-referenced-by-count":4,"title":["Lingual alveolar soft part sarcoma responsive to pazopanib"],"prefix":"10.1097","volume":"96","author":[{"given":"Tomoyasu","family":"Yoshihiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Nio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Yasumatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Jiroumaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-52-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(02)00592-7","article-title":"Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: alveolar soft part sarcoma","volume":"136","author":"Sandberg","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"R2-52-20210226","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/01913129809103349","article-title":"Alveolar soft-part sarcoma: a review of the pathology and histogenesis","volume":"22","author":"Ordonez","year":"1998","journal-title":"Ultrastruct Pathol"},{"key":"R3-52-20210226","doi-asserted-by":"crossref","first-page":"e48023","DOI":"10.1371\/journal.pone.0048023","article-title":"Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets","volume":"7","author":"Covell","year":"2012","journal-title":"PLoS ONE"},{"key":"R4-52-20210226","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.onc.1204074","article-title":"The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25","volume":"20","author":"Ladanyi","year":"2001","journal-title":"Oncogene"},{"key":"R5-52-20210226","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/1097-0142(20010201)91:3<585::AID-CNCR1038>3.0.CO;2-0","article-title":"Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution","volume":"91","author":"Portera","year":"2001","journal-title":"Cancer"},{"key":"R6-52-20210226","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1002\/cncr.27582","article-title":"Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial","volume":"118","author":"Wagner","year":"2012","journal-title":"Cancer"},{"key":"R7-52-20210226","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.2012.47.4288","article-title":"Cediranib for metastatic alveolar soft part sarcoma","volume":"31","author":"Kummar","year":"2013","journal-title":"J Clin Oncol"},{"key":"R8-52-20210226","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2559.2004.01966.x","article-title":"Lingual alveolar soft part sarcoma; 14 cases: novel clinical and morphological observations","volume":"45","author":"Fanburg-Smith","year":"2004","journal-title":"Histopathology"},{"key":"R9-52-20210226","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/annonc\/mdv530.09","article-title":"Pazopanib treatment in alveolar soft part sarcomas","volume":"26","author":"Kobayashi","year":"2015","journal-title":"Ann Oncol"},{"key":"R12-52-20210226","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/RLU.0b013e3182817b09","article-title":"CT, MRI, and FDG PET\/CT in a patient with alveolar soft part sarcoma","volume":"39","author":"Dong","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R13-52-20210226","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.mnm.0000237986.31597.86","article-title":"18F-FDG PET and PET\/CT for detection of pulmonary metastases from musculoskeletal sarcomas","volume":"27","author":"Iagaru","year":"2006","journal-title":"Nucl Med Commun"},{"key":"R14-52-20210226","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.4161\/cc.6.14.4484","article-title":"MiT transcription factor associated malignancies in man","volume":"6","author":"Davis","year":"2007","journal-title":"Cell Cycle"},{"key":"R15-52-20210226","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0277-5379(87)90089-7","article-title":"Adriamycin versus Epirubicin in advanced soft tissue sarcomas. A randomized phase II\/phase III- study of the EORTC Soft tissue and Bone Sarcoma group","volume":"23","author":"Mouridsen","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R16-52-20210226","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.1998.16.4.1438","article-title":"Dose-intensive chemotherapy with ifosfamide, epirubicin and filgastrim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study","volume":"16","author":"Reichardt","year":"1998","journal-title":"J Clin Oncol"},{"key":"R17-52-20210226","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0959-8049(03)00264-8","article-title":"Chemotherapy in alveolar soft part sarcomas. What do we know?","volume":"39","author":"Reichardt","year":"2003","journal-title":"Eur J Cancer"},{"key":"R18-52-20210226","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(06)70729-X","article-title":"Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma","volume":"7","author":"Azizi","year":"2006","journal-title":"Lancet Oncol"},{"key":"R19-52-20210226","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","article-title":"TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"},{"key":"R20-52-20210226","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5301\/tj.5000617","article-title":"Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma","volume":"103","author":"Jagodzi\u0144ska-Mucha","year":"2017","journal-title":"Tumori"},{"key":"R21-52-20210226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: clinical development of a potent anti-angiogenic drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"R22-52-20210226","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"R23-52-20210226","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/1078-0432.CCR-08-2050","article-title":"Response to sunitinib malate in advanced alveolar soft part sarcoma","volume":"15","author":"Stacchiotti","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:38:58Z","timestamp":1620959938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201711030-00052"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008470","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}